BiotechTube

SYNB1618 + SYNB1934

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonuria

Conditions

Phenylketonuria

Trial Timeline

Aug 25, 2020 → Oct 7, 2022

NCT ID
NCT04534842

About SYNB1618 + SYNB1934

SYNB1618 + SYNB1934 is a phase 2 stage product being developed by Synlogic for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT04534842. Target conditions include Phenylketonuria.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04534842Phase 2Completed

Competing Products

20 competing products in Phenylketonuria

See all competitors
ProductCompanyStageHype Score
SYNB1934v1 + PlaceboSynlogicPhase 3
69
SYNB1618 + PlaceboSynlogicPhase 1/2
33
Kuvan®MerckPhase 3
77
Kuvan®MerckApproved
85
SAR444836SanofiPhase 1/2
40
KuvanBioMarin PharmaceuticalPre-clinical
20
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
20
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
49
BMN 307BioMarin PharmaceuticalPhase 1/2
38
SapropterinBioMarin PharmaceuticalPre-clinical
20
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
74
BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
74
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
74
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
82
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
49

Other Products from Synlogic

SYNB1934v1 + PlaceboPhase 3
69
SYNB1618 + PlaceboPhase 1/2
33
SYNB1020Phase 1/2
33
SYNB1891 + AtezolizumabPhase 1
25
Placebo + SYNB1020Phase 1
25